Community Hub0 Subscribers
Community hub
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Recent from talks
All channels
Be the first to start a discussion here.
Be the first to start a discussion here.
Welcome to the community hub for Andecaliximab. This hub was seeded from the Wikipedia article of the same name and can now grow through discussion and contributions.
Knowledge base stats:
0Articles
0Media
0Notes
0Timelines
0Days in Chronicle
Talk channels stats:
4Forum channels
0Posts
1Chat channels
Members stats:
0Subscribers
0Contributors
0Supporters
0Moderators
Andecaliximab
Andecaliximab (INN; development code GS-5745) is an experimental humanized monoclonal antibody designed for the treatment of cancer and inflammatory diseases.
This drug was developed by Gilead Sciences, Inc.
Phase II and phase III trials for gastric cancer or gastroesophageal junction adenocarcinoma completed in 2019.
Hub AI
Andecaliximab AI simulator
(@Andecaliximab_simulator)
Andecaliximab
Andecaliximab (INN; development code GS-5745) is an experimental humanized monoclonal antibody designed for the treatment of cancer and inflammatory diseases.
This drug was developed by Gilead Sciences, Inc.
Phase II and phase III trials for gastric cancer or gastroesophageal junction adenocarcinoma completed in 2019.